CIK 1479355
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2016-Q3. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 60.17% | 14 |
| Pharmaceuticals & Biotechnology | 39.83% | 7 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DBVTF | DBV Technologies | Unclassified | 33.47% |
| 2 | HRTX | HERON THERAPEUTICS, INC. /DE/ | Health Care | 15.43% |
| 3 | CHRS | Coherus Oncology, Inc. | Health Care | 9.25% |
| 4 | BCRX | BIOCRYST PHARMACEUTICALS INC | Health Care | 7.86% |
| 5 | FLAMEL TECH ADR | Unclassified | 5.59% | |
| 6 | RA PHARMACEUTICALS INC | Unclassified | 3.80% | |
| 7 | Adverum Biotechnologies, Inc. | Unclassified | 3.44% | |
| 8 | LPCN | Lipocine Inc. | Health Care | 3.36% |
| 9 | COLUCID PHARMACEUTICALS INC | Unclassified | 2.67% | |
| 10 | AXOVANT SCIENCES LTD | Unclassified | 2.46% |
7/21 names classified · sector 39.8% of weight · industry 39.8% · mkt cap 36.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 39.8% of the book is sector-classified (unclassified names shown, never dropped).
Only 17% of book weight classified — the grid is NOT representative of the whole book.
Classified: 17.1% of book weight (2/9 names) · unclassified 82.9%: DBVTF, , HRTX, LPCN, ASND, AKTX, CTMX. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DBVTFDBV Technologies | 456,893 | $31M | 33.5% | HOLD |
| 2 | HRTXHERON THERAPEUTICS INC | 1,095,734 | $14M | 15.4% | HOLD |
| 3 | CHRSCOHERUS ONCOLOGY INC | 305,505 | $9M | 9.2% | HOLD |
| 4 | BCRXBIOCRYST PHARMACEUTICALS INC | 1,155,104 | $7M | 7.9% | ADD 15% |
| 5 | FLAMEL TECH ADR | 500,000 | $5M | 5.6% | HOLD |
| 6 | RA PHARMACEUTICALS INC | 232,500 | $4M | 3.8% | NEW |
| 7 | Adverum Biotechnologies, Inc. | 1,102,735 | $3M | 3.4% | HOLD |
| 8 | LPCNLIPOCINE INC NEW | 849,921 | $3M | 3.4% | HOLD |
| 9 | COLUCID PHARMACEUTICALS INC | 68,190 | $2M | 2.7% | HOLD |
| 10 | AXOVANT SCIENCES LTD | 184,110 | $2M | 2.5% | HOLD |
| 11 | OCERA THERAPEUTICS INC COM | 912,050 | $2M | 2.1% | ADD 6% |
| 12 | ASNDASCENDIS PHARMA A/S | 90,000 | $2M | 2.0% | HOLD |
| 13 | EDGE THERAPEUTICS INC | 135,000 | $2M | 1.8% | HOLD |
| 14 | STEMLINE THERAPEUTICS INC | 135,420 | $1M | 1.6% | HOLD |
| 15 | ALCOBRA LTD | 658,910 | $1M | 1.5% | HOLD |
| 16 | ARCA biopharma Inc | 462,399 | $1M | 1.4% | HOLD |
| 17 | AKTXAKARI THERAPEUTICS PLC | 158,352 | $1M | 1.2% | HOLD |
| 18 | CTMXCYTOMX THERAPEUTICS INC. | 64,200 | $706,000 | 0.8% | HOLD |
| 19 | AUDENTES THERAPEUTICS INC. | 15,000 | $274,000 | 0.3% | HOLD |
| 20 | Sierra Oncology, Inc. | 56,056 | $84,000 | 0.1% | HOLD |
| 21 | AEGLEA BIOTHERAPEUTICS INC | 6,000 | $26,000 | 0.0% | HOLD |
Where this firm's principals came from and which firms its alumni went on to found.
